Each week, I track the most consequential startup developments across Europe to help investors, asset managers, and financial professionals decode where private capital is moving, which sectors are heating up, and what early-stage activity tells us about broader market trends. This week’s deal flow is particularly telling: defence tech is attracting institutional-scale capital, AI valuations continue to stretch the imagination, and biotech is quietly building a compelling investment case across the continent.
The headline deal of the week belongs to UFORCE, a Ukrainian-origin defence technology company headquartered in London, which closed a staggering $700 million Series A co-led by Valor Equity Partners and the UK National Wealth Fund at a $6 billion valuation. At that size, this is less a startup funding round and more a capital markets event in its own right, signalling that autonomous defence systems have crossed into institutional investment territory. For asset managers with exposure to defence equities, the competitive pressure from well-capitalised private players like UFORCE is now a material consideration.
Staying in the defence sector, Helsing, the German defence AI startup backed by Daniel Ek, launched a dedicated military intelligence platform explicitly targeting European sovereign clients — and positioning itself as a direct challenger to Palantir. The strategic ambition is significant: European governments are actively seeking domestic alternatives to US defence technology platforms, and Helsing is well-placed to capture that procurement pipeline.
On the biotech front, Amsterdam-based VectorY Therapeutics closed a €74.5 million financing round to advance its vectorised antibody therapies for ALS and Huntington’s disease. This is a meaningful raise for a European biotech at this stage, and the participation of both new and existing investors suggests strong conviction around its clinical pipeline — worth watching for anyone tracking pre-IPO biotech opportunities in the Netherlands.
The AI investment story of the week is undoubtedly Typesafe, a Swedish AI developer tools startup whose valuation rocketed from 2 billion to 74 billion Swedish kronor within a single month, triggering a bidding war among prominent Swedish tech investors. The velocity of that re-rating — a 37x move in weeks — reflects both the ferocity of AI investor appetite in the Nordics and the liquidity risks that come with privately-negotiated valuations detached from fundamental anchors.
Meanwhile, Mistral AI received formal recognition at the Dublin EU Summit as Europe’s sole frontier AI developer, with CEO Arthur Mensch leading the AI discussion among EU heads of state. That political endorsement carries real financial weight: regulatory tailwinds, potential sovereign procurement contracts, and increased visibility among European institutional investors all strengthen Mistral’s pre-IPO positioning.
In healthtech, Incision raised €4 million from HERAN Partners to pursue US market entry, while Czech medtech Kardi AI secured €5.3 million Series A funding to scale its long-term ECG monitoring platform into new European and Asian markets. Both rounds underscore the continued appetite for capital-efficient digital health models with clear cross-border commercial pathways.
The week also produced a cautionary tale for investors evaluating late-stage consumer startups: French beauty-tech company Jolimoi entered judicial liquidation despite having raised €10.5 million, generated €20 million in 2024 revenue, and reportedly reached profitability in 2025. The collapse illustrates how structural fragility — in this case, dependency on a network of 10,000 commission-based stylists — can undermine otherwise healthy top-line metrics.
Finally, a macro signal worth noting: a new Stripe report found that 73% of European tech leaders cite regulatory burden as a growing constraint on innovation. For investors pricing European startup risk, this is a persistent structural headwind that affects both growth trajectories and exit timelines across the ecosystem.
Taken together, this week’s activity paints a picture of a European startup ecosystem that is maturing in fits and starts — capable of producing defence unicorns and frontier AI champions, while still grappling with regulatory friction and the occasional high-profile implosion. For capital markets professionals, the signal is clear: sector selection and structural diligence matter more than ever in European venture.
— Maurizio Savino, Editor in Chief, EU Finance News